drugset / Trial / NCT03932916

Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects

NCT03932916

Non-randomizedSequentialOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects.

Timeline

Start
2019-07-02
Primary completion
2020-08-06
Completion
2020-09-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 5 mg Oral
Subject Donepezil Pamoate Unknown 17 mg Intramuscular
Subject Donepezil Pamoate Unknown 34 mg Intramuscular

Indications

No indication recorded.